BlackRock Institutional Trust’s Blueprint Medicines BPMC Stock Holding History

BlackRock Institutional Trust’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$16.1M	Buy	573,342 +150,549	+36%	+$4.54M	﹤0.01%	2127
2016 Q3	$12.6M	Buy	422,793 +94,163	+29%	+$2.34M	﹤0.01%	2197
2016 Q2	$6.66M	Buy	328,630 +96,761	+42%	+$1.76M	﹤0.01%	2535
2016 Q1	$4.18M	Buy	231,869 +17,453	+8%	+$303K	﹤0.01%	2756
2015 Q4	$5.65M	Buy	214,416 +63,957	+43%	+$1.44M	﹤0.01%	2647
2015 Q3	$3.21M	Buy	150,459 +28,199	+23%	+$780K	﹤0.01%	2916
2015 Q2	$3.24M	Buy	+122,260	New	+$3.49M	﹤0.01%	2925

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock Institutional Trust's BPMC Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Blueprint Medicines (BPMC) stake by 36% in Q4 2016, buying an estimated $4.54M and bringing the position to 573,342 shares worth $16.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2127.

BlackRock Institutional Trust first reported a position in BPMC in Q2 2015 and has held it in 7 quarters since. 103 funds tracked by Wall St. Rank hold BPMC as of Q4 2016.

BlackRock Institutional Trust held 573,342 shares of Blueprint Medicines worth $16.1M as of Q4 2016.
BlackRock Institutional Trust bought 150,549 Blueprint Medicines shares in Q4 2016, an estimated $4.54M.
Blueprint Medicines made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2127 holding.
BlackRock Institutional Trust first reported a position in Blueprint Medicines in Q2 2015 and has held it in 7 quarters since.
103 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.